Bellevue Group AG Has $195.11 Million Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Bellevue Group AG lessened its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 8.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,819,482 shares of the biopharmaceutical company’s stock after selling 246,918 shares during the period. Intra-Cellular Therapies comprises approximately 3.0% of Bellevue Group AG’s holdings, making the stock its 7th biggest position. Bellevue Group AG owned approximately 2.67% of Intra-Cellular Therapies worth $195,108,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC boosted its stake in shares of Intra-Cellular Therapies by 9.7% during the 1st quarter. Avoro Capital Advisors LLC now owns 2,475,000 shares of the biopharmaceutical company’s stock worth $171,270,000 after acquiring an additional 219,445 shares during the last quarter. Affinity Asset Advisors LLC bought a new stake in Intra-Cellular Therapies during the first quarter valued at about $3,460,000. EntryPoint Capital LLC increased its position in Intra-Cellular Therapies by 138.7% in the first quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,259 shares in the last quarter. Natixis raised its stake in shares of Intra-Cellular Therapies by 165.9% in the first quarter. Natixis now owns 3,733 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 2,329 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Intra-Cellular Therapies by 106.0% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 17,023 shares of the biopharmaceutical company’s stock valued at $1,178,000 after buying an additional 8,760 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ITCI shares. Mizuho increased their target price on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. The Goldman Sachs Group lifted their target price on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research note on Wednesday, April 17th. JPMorgan Chase & Co. upped their target price on shares of Intra-Cellular Therapies from $75.00 to $78.00 and gave the stock an “overweight” rating in a report on Wednesday, June 12th. Needham & Company LLC raised their price target on Intra-Cellular Therapies from $94.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Finally, UBS Group restated a “neutral” rating and issued a $83.00 price objective (down from $85.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and an average price target of $94.83.

Insider Buying and Selling

In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.57, for a total transaction of $337,193.34. Following the completion of the sale, the director now owns 116,600 shares of the company’s stock, valued at approximately $8,811,462. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Rory B. Riggs sold 4,462 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.57, for a total value of $337,193.34. Following the completion of the transaction, the director now directly owns 116,600 shares in the company, valued at $8,811,462. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Nostrand Robert L. Van sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $75.91, for a total value of $1,518,200.00. Following the completion of the sale, the director now owns 9,690 shares in the company, valued at approximately $735,567.90. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Stock Down 0.6 %

Shares of ITCI traded down $0.45 during mid-day trading on Friday, hitting $80.39. 625,487 shares of the company traded hands, compared to its average volume of 1,508,061. The company has a market capitalization of $8.49 billion, a PE ratio of -69.30 and a beta of 1.01. The business has a 50 day moving average of $71.53 and a 200 day moving average of $69.91. Intra-Cellular Therapies, Inc. has a 1-year low of $45.50 and a 1-year high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.15. The company had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. Intra-Cellular Therapies’s revenue was up 52.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) EPS. As a group, research analysts expect that Intra-Cellular Therapies, Inc. will post -0.54 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.